Gail K. Naughton, Ph.D., CEO, Chairman of the Board
In addition to being the Dean of the College of Business Administration at San Diego State University since August 2002, Dr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Executive Officer and Chairman of the Board for the Company. She has spent more than 15 years extensively researching the tissue engineering process, holds more than 90 U.S. and foreign patents and has been extensively published in the field. gnaughton@histogeninc.com 
| During her tenure at Advanced Tissue Sciences, where she was the company's co-founder and co-inventor of its core technology, Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world's first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton sits on the Board of directors of the City of Hope, Celera (NASDAQ: CRA) and CR Bard (NYSE: BCR). |
Stephen Chang, Ph.D., VP of Research and Development, New York Stem Cell Foundation
Dr. Stephen Chang joined NYSCF in 2010 as the Vice President of Research and Development after serving as Chief Scientific Officer of Stemgent upon the company's founding in 2008. He was previously the CEO of Multicell Technologies and continues as a director of this company. Prior to that, he was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in 2005. Previously, he was chief science officer (CSO) and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004. He has also held senior management positions at Chiron and Viagene.
| Dr. Chang is president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative lifesaving medications. He is also a board member of Histogen, Inc., a privately held company in regenerative medicine. Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.
Dr. Chang's research interest is in the area of translational applications of basic science to pharmaceutical products. He holds over 20 patents and has initiated or been responsible for over nineteen IND involving novel biologic and small molecule compounds. A biochemical geneticist by training, Dr. Chang has been involved in HIV therapeutics, cancer therapeutics, vaccine applications, arthritis, Multiple sclerosis, ophthalmology, hepatitis and stem cell research.
|
Stephen Badylak, D.V.M., Ph.D., M.D., Director of the Board, Chair, Scientific Advisory Board
Dr. Badylak is a Professor in the Department of Surgery, a deputy director of the McGowan Institute for Regenerative Medicine (MIRM) at the University of Pittsburgh, and Director of the Center for Pre-Clinical Tissue Engineering within the Institute. In 1976, Dr. Badylak received his D.V.M. from Purdue University. He then obtained an M.S. in Clinical Pathology from Purdue University in 1978, a Ph.D. in Anatomic Pathology from Purdue University in 1981 and graduated with highest honors with a M.D. from Indiana University Medical School in 1985.
| Dr. Badylak practiced veterinary medicine at a mixed animal practice in Glenwood, Illinois and in Hobart, Indiana. Dr. Badylak began his academic career at Purdue University as an Assistant Research Scholar at the Hillenbrand Biomedical Engineering Center in 1983, and subsequently held a variety of positions including Postdoctoral Research Associate (1985), Associate Research Scholar (1988) and served as the Director of the Hillenbrand Biomedical Engineering Center from 1993-1998. Dr. Badylak held a dual appointment as an Associate Professor within the Department of Veterinary Physiology and Pharmacology and also served as the Head Team Physician for the Athletic Department for 16 years (1985-2001). Prior to his move to Pittsburgh, Dr. Badylak served as Senior Research Scientist within the Department of Biomedical Engineering at Purdue University and Adjunct Associate Professor of Pathology and Laboratory Medicine at the Indiana University School of Medicine.
Dr. Badylak holds over 40 U.S. patents, 200 patents worldwide, has authored more than 180 scientific publications and 12 book chapters. He has served as the Chair of the Purdue University Tissue Engineering Advisory Board, chair of the Study Section for the Small Business Innovative Research (SBIR) at the National Institutes of Health (NIH), and as chair of the Bioengineering, Technology, and Surgical Sciences (BTSS) Study Section at NIH. Dr. Badylak has either chaired or been a member of the Scientific Advisory Board to several major medical device companies.
Dr. Badylak is a Fellow of the American Institute for Medical and Biological Engineering, a charter member of the Tissue Engineering Society International, and currently the North American Member at Large to the Tissue Engineering Regenerative Medicine International Society (TERMIS). He is also a member of the Society for Biomaterials and the International Society for Applied Cardiovascular Biology (ISACB). Dr. Badylak is the Associate Editor for Tissue Engineering and for the journal Cells, Tissues, Organs.
For his contributions to his field, he has been featured in several publications and has been the recipient of multiple awards, including the Sigma Xi Scientific Society 2002 Research Award, the Pittsburgh Business Times Hero in Health Care Innovation & Research for 2005, the 2005 Carnegie Science Center Award for Excellence, and the 2005 Clemson Award from the Society for Biomaterials. |
Leonard H. Lavin, Founder & Chairman Emeritus, Alberto-Culver Company
Leonard H. Lavin is the founder, Chairman Emeritus and a director of the Alberto-Culver Company (NYSE: ACV), a $1.4 billion company which manufactures, markets and distributes beauty, personal care and household/ grocery products in over 120 countries. Alberto-Culver's leading global personal care products include Alberto VO5, TRESemme, St. Ives, Nexxus, Soft & Beautiful, Motions and Just For Me and a group of important regional brands.
| The company also markets leading household and grocery products including Mrs. Dash and Static Guard, and operates a custom label beauty products manufacturing operation.
Until November, 2006 the company operated Sally Beauty Company and its Beauty Systems Group in addition to its consumer products unit. Alberto-Culver acquired Sally, a small chain in New Orleans, in 1969 and grew it into the largest distributor of professional beauty products in the world with over 3300 stores. Combined, the consumer products and beauty distribution businesses had sales of $3.75 billion. Late in 2006, the company separated these operations into separately-traded public companies, Alberto-Culver Company and Sally Beauty Holdings (NYSE: SBH).
Mr. Lavin began his career with Lucien Lelong after graduation from the University of Washington. He entered the Navy prior to World War II and served four years of sea duty, participating in nine invasions.
In 1946 he joined Halgar, Inc., a company specializing in toiletries products. He advanced up the ranks, became second in command, and helped build the organization into a major entity. He left Halgar to form the Excello Sales Agency with exclusive selling and advertising rights for a new spray deodorant that soon became the leading antiperspirant in the U.S. After the product became number one in its category, Mr. Lavin sold his interests and formed Leonard H. Lavin & Company, a national company responsible for sales, distribution, advertising and promotion of nationally known toiletry and proprietary products. He then returned to Halgar and purchased the company.
After several years, Leonard H. Lavin & Company grew to become a major factor in the health and beauty aids industry. Mr. Lavin had further expanded his business by purchasing several national manufacturing companies in this field.
In 1955, Mr. Lavin bought the Alberto-Culver Company, at the time a regional manufacturer of professional beauty supplies serving the West Coast. He discontinued all of the company's products except for one -- Alberto VO5 Conditioning Hairdressing. This product was the key to his acquisition and the brand on which he rapidly built the company.
The company has grown from a one product firm to an international organization that manufactures worldwide, sells products in more than 100 countries with annual sales of over three billion dollars. It became a public company in 1961 and has been listed on the New York Stock Exchange since 1965. Alberto-Culver is one of the leaders in the packaged goods field and a major national advertiser. The company has earned a reputation for innovation, both in new product development and advertising, and since 1955 has created and built numerous new product categories in the toiletries and household/ grocery markets.
Mr. Lavin has been a true innovator in the advertising area. He was among the first package goods marketers to recognize the value of television in building brands. He bought initial sponsorship in some of television's pioneering shows such as "What's My Line" and "The Smothers Brothers Show". It was his concept, and his fight through the courts that brought the 30-second, and the 15-second commercial to television.
He has been active in many professional and philanthropic organizations. He is a lifetime trustee of Northwestern Memorial Hospital and a former director of Continental Illinois Bank Corporation. He is a lifetime trustee of the University of Chicago Cancer Research Center and serves on the board of Junior Achievement and on the Museum of Science and Industry President's Council. He is a member of the Chicago Crime Commission, Economic Club of Chicago, Executives' Club of Chicago, Mid-America Committee, Chicago Club, Commercial Club and the Chicago Council on Foreign Relations.
He has been the recipient of numerous awards and honors for his philanthropic, civic and business endeavors. Early in his career he was presented with a Gold Medal as the International Marketing Man of the Year, in 1988 he was named "Citizen of the Year" by the City Club of Chicago, in 1989 he was presented with the "Marketing Statesman of the Year" award by the Sales and Marketing Executives of Chicago, in 1990 he received the Steuart Henderson Britt Award for Marketing Achievement from the American Marketing Association, and in 1993 he was inducted into the Merchandising Executives Club Hall of Fame and the Junior Achievement Chicago Business Hall of Fame, in 1995 was inducted into the Chicagoland Entrepreneurship Hall of Fame and this year was given a "Lifetime Achievement Award in Entrepreneurship" by Ernst & Young as a part of their Entrepreneur of the Year Awards program. By appointment of the Governor of Illinois, Mr. Lavin was named a Lincoln Laureate, the highest honor the state can give to its native-born citizens.
In 1992, Prentice Women's Hospital and Maternity Center opened the Alberto-Culver Women's Health Center, a state-of-the-art library, education and conference facility which provides health information to women regardless of their ability to pay. Mr. and Mrs. Lavin, and their daughter Carol, have been the guiding forces behind this effort.
Mr. Lavin is also actively involved in thoroughbred horse breeding. He is proprietor of Glen Hill Farm in Ocala, Florida, home base for the horse breeding, racing and selling business he has built into a significant presence in the thoroughbred industry. Glen Hill Farm's One Dreamer won the 1994 Breeder's Cup Distaff. Here also Mr. and Mrs. Lavin are active in philanthropic activities. A major study of jockey and trainer injuries conducted by the Rehabilitation Institute of Chicago and funded by the Lavins was presented at the University of Arizona's Symposium on Racing in December 1994 and published in 1995.
Mr. Lavin's memoirs Winners Make It Happen: Reflections of a Self-Made Man were published in 2003 by Bonus books. He currently lectures in the Entrepreneurship program at San Diego State University in California. |
Susan Baxter, CSUPERB Executive Director
Dr. Baxter has over twenty years of research and management experience in business, nonprofit and academic settings. Currently she is the Executive Director of the California State University Program for Education and Research in Biotechnology (CSUPERB), a system-wide program that supports biotechnology research, sponsors innovative new curriculum, and serves as a liaison for the CSU and government, educational and industry partners.
| Previously, Baxter held positions of chief operating officer and board member at the National Center for Genome Resources, vice president of research and genome analysis at GeneFormatics, and research scientist at the Wadsworth Center, New York State Department of Health. |
Jonathan Jackson
A few years after completing his degree in Business Management in London, Jonathan Jackson set up his own company to develop commercial real estate in Central Europe. Over the last 20 years he has currently under development and developed more than 6,000,000 sqft of space. Since selling a portfolio of completed assets in early 2007 in one of the largest deals in Central Europe, Mr. Jackson has diversified and invested over $15M in different business sectors, both in the USA and Europe, with great success.
Joel Korsunsky, Chief Operating Officer, Secure Medical
Joel Korsunsky joined Secure Medical as its Chief Operating Officer in 2005. He oversees operations and business development in both Secure Medical Incorporated (SMI) and Phoenix Kiosk (a wholly owned subsidiary of SMI). Mr. Korsunsky also leads the Company's telemedicine projects, such as the Health Pod and the OurDoctor platforms. He represents SMI as its industry council spokesperson at the American Telemedicine Association and the Center for Telehealth Law.
| He has been active in working with statute revisions at a political level in a number of states on various policy revisions, and committees ranging from telemedicine to technology. Mr. Korsunsky has owned and operated many businesses, has served as a manager in executive capacities for more than 30 years, and has extensive experience in the pharmaceutical and mail order industries. He has managed efforts in marketing and human resources, and has served on many boards of directors in industries ranging from real estate to retail. He holds a B.A. from the University of Manitoba in Winnipeg, Manitoba, Canada. |
Scientific Advisory Board
Neil Sadick, M.D., F.A.A.D, F.A.A.C.S., F.A.C.P., F.A.C.P.h
A prominent dermatologist and researcher, Neil Sadick holds positions as Clinical Professor of Dermatology at Weill Cornell Medical College and President of the Cosmetic Surgery Foundation, in addition to being the founder of Sadick Dermatology, a leading aesthetic medicine practice in New York. He is board certified in Dermatology, Cosmetic Surgery, Internal Medicine, and Hair Transplantation.
| Dr. Sadick is author, or co-author, of more than 500 articles in peer-reviewed scientific journals and has contributed more than 75 chapters of medical books. In addition, he has written or edited more than 10 books on cosmetic surgery, hair, and vein treatment. Dr. Sadick has also been a guest lecturer at more than 500 medical seminar classes and workshops worldwide.
Dr. Sadick is the recipient of The Jobst Award for Research in Vascular Diseases, American Cancer Society Research Award, American Medical Association's Continuing Medical Education Award, and is a lead research physician for Merck Pharmaceutical, ESC Medical, Jobst Biersdorf, and Aesclepion.
|
David Easter, M.D., F.A.C.S.
David Easter is a general surgeon whose passion is education, with special interests in surgical oncology, diseases of the gastrointestinal tract, and laparoscopic surgery. As a recent Director of the Clinical Oncology Programs for the Rebecca and John Moores UCSD Cancer Center, Dr. Easter organized the Cancer Center's clinical and research efforts to provide the finest possible care for cancer patients. He currently serves as Professor of Clinical Surgery at UCSD, and is dedicated to providing the best in surgical care through translating the latest research discoveries into clinical practice.
| Dr. Easter also participates in the Graduate Medical Education Committee as the Program Director for General Surgery, the Patient Care Committee, and a number of other groups that influence patient care at UCSD. Recently, UCSD honored Dr. Easter as the first UCSD recipient of the Vice Chancellor's Excellence in Clinical Care award. At UCSD and in national surgical organizations, Dr. Easter is a leader in developing new ways to ensure that medical students and surgical residents receive excellent training in the increasingly complex world of surgery.
In his research at UCSD, Dr. Easter conducts clinical and basic science studies in many areas, including techniques and results of laparoscopic surgery procedures, the causes and treatment of gastrointestinal reflux disease, approaches to surgical training, and empathy in doctor-patient communication. One of his recent studies addressed ways for physicians to improve their ability to help cancer patients understand and discuss their fears during a clinic visit. Dr. Easter conducts patient clinics and performs surgeries at UCSD's medical center in Hillcrest. He is certified by the American Board of Surgery.
|
Craig L. Ziering, D.O., F.A.O.C.D.
Dr. Craig L. Ziering is a leading authority in hair transplant surgery, with more than 16 years of specialized experience in hair restoration. In addition to performing over 12,000 hair transplant procedures, he is an author, lecturer, trusted surgeon to physicians, and innovator in the field. As founder and medical director of Ziering Medical, he currently operates hair restoration centers throughout California, Utah and Nevada.
| Dr. Ziering is certified by both the American Board of Hair Restoration Surgery and the American Osteopathic Board of Dermatology, serves on the advisory board for companies including Merck and Lexington International, and is Surgical Faculty for the Procedural Dermatology Fellowship at the University of California at Irvine.
As a recognized expert in the art and science of hair transplant surgery, Dr. Ziering is a frequent guest on television and radio programs including The Today Show. In addition to being invited to perform the first hair transplant procedure on the ABC hit Extreme Makeover, he was chosen to premier his "sneak-peek long hair transplant" procedure on the cutting edge E! reality show Dr. 90210.
In 2003, Dr. Ziering's WHORL classification system was awarded "Most Original New Idea" by the ISHRS scientific assembly. He remains an active participant in research, and serves as a strong advocate of hair cloning as a future treatment for hair loss.
|
Dale P. DeVore, Ph.D.
Dale Devore is currently Vice President of Research & Development for BioForm Medical, Inc. Prior to joining BioForm, he was a consultant to several major medical device companies, including three involved in developing dermal filler products. He was previously a member of the Board of Directors and Senior Vice President of Research & Development and the Chief Scientific Officer for Collagenesis, Inc., and inventor/ co-inventor of all of the Company's technologies.
| Dr. DeVore is considered one of the experts in the development and medical application of biomaterials and has authored/ co-authored more than 60 articles in the field. Dr. DeVore has presented more than 300 technical presentations and has authored more than 50 patents on the processing and medical use of natural biomaterial compositions. Dr. DeVore was also the Chief Scientific Officer for the Company's predecessor, Autogenesis Technologies, Inc. from 1988 to 1994. From 1985 to 1988, Dr. DeVore was Director-Product Development, VP-Scientific Affairs and Director for MedChem Products, Inc., where he co-invented the currently commercialized AMVISC® Plus, an ophthalmologic collagen-based compound for cataract surgery (now distributed by Bausch & Lomb). From 1979 to 1985, Dr. DeVore was a Senior Research Specialist with 3M, where he was nominated for the 3M Circle of Technical Excellence. Prior to 1979, Dr. DeVore was a research biochemist at Battelle Memorial Institute where he was awarded seven NIH grants and two Arthritis Foundation grants. While at Battelle, Dr. DeVore initiated in-house projects to develop collagen-based materials for human implant use. Dr. DeVore holds a B.S., M.S., and Ph.D. in biochemistry from Rutgers University. |
